Beijing Scitop Bio Tech Co Ltd
Beijing Scitop Bio-tech Co., Ltd. researches, develops, produces, and sells probiotic, postbiotics, and microecologival preparations for animals and plants in China. It provides probiotic and postbiotics for gastrointestinal health, immune regulation, oral health, sleep aid and stress relief, women's health, slimming and fat reduction, kidney and liver protection, blood sugar regulation, allergy … Read more
Beijing Scitop Bio Tech Co Ltd (300858) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.024x
Based on the latest financial reports, Beijing Scitop Bio Tech Co Ltd (300858) has a cash flow conversion efficiency ratio of 0.024x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥44.72 Million) by net assets (CN¥1.83 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Beijing Scitop Bio Tech Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Beijing Scitop Bio Tech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Beijing Scitop Bio Tech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing Scitop Bio Tech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tokmanni Group Oyj
HE:TOKMAN
|
-0.003x |
|
Kolon Life Science Inc
KQ:102940
|
0.007x |
|
Vietnam Construction and Import Export JSC
VN:VCG
|
0.078x |
|
NVE Corporation
NASDAQ:NVEC
|
0.047x |
|
Saratoga Investment Corp
NYSE:SAR
|
0.018x |
|
Solus Advanced Materials Co Ltd
KO:336370
|
0.006x |
|
Latitude Group Holdings Ltd
AU:LFS
|
-0.096x |
|
Turaco Gold Ltd
AU:TCG
|
-0.118x |
Annual Cash Flow Conversion Efficiency for Beijing Scitop Bio Tech Co Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Beijing Scitop Bio Tech Co Ltd from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.79 Billion | CN¥142.11 Million | 0.079x | +28.30% |
| 2023-12-31 | CN¥1.73 Billion | CN¥107.27 Million | 0.062x | -29.26% |
| 2022-12-31 | CN¥1.70 Billion | CN¥148.46 Million | 0.088x | -23.23% |
| 2021-12-31 | CN¥967.40 Million | CN¥110.27 Million | 0.114x | +59.44% |
| 2020-12-31 | CN¥932.59 Million | CN¥66.67 Million | 0.071x | -70.91% |
| 2019-12-31 | CN¥399.83 Million | CN¥98.27 Million | 0.246x | -17.16% |
| 2018-12-31 | CN¥301.83 Million | CN¥89.55 Million | 0.297x | -0.72% |
| 2017-12-31 | CN¥281.09 Million | CN¥84.00 Million | 0.299x | +77.64% |
| 2016-12-31 | CN¥194.57 Million | CN¥32.73 Million | 0.168x | +229.95% |
| 2015-12-31 | CN¥52.67 Million | CN¥2.69 Million | 0.051x | -- |